Evidence map›Paper›PMID 16014954›Full record

ArticleJournal of virology2005

Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps.

Joshua C Grieger, Richard J Samulski

Abstract readComparative Study
In one paragraph

Article in Journal of virology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 238 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
238citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

238 citing papers in PubMed, 1 synthesis or guideline pooled it, 401 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Developing Optogenetic Approaches to Study CaCold Spring Harbor perspectives in biology · 2026
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Clinical translation of epigenome editing technologies.Current opinion in biomedical engineering · 2026
    Article
  16. Article
  17. Prime editing of a pathogenicScience translational medicine · 2026
    Article
  18. Article
  19. Review
  20. Article

178 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Joshua C GriegerCurriculm in Genetics and Molecular Biology and Gene Therapy Center, University of North Carolina at Chapel Hill, 27599-7352, USA.
Richard J Samulski
University of North Carolina at Chapel Hill · US

Funding

Vector CoreP30DK065988 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Richard Charles Boucher, Martina Gentzsch · 2004 to 2026
$26.5M
Respiratory Syncytial Virus Based Vectors for CFTRP01HL051818 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVIS, WILLIAM C. · 1993 to 2008
$16.0M
TRANSPORT AND DELIVERY OF ANTISNESE OLIGONUCLEOTIDESP01GM059299 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JULIANO, RUDOLPH · 2000 to 2010
$11.7M
Resolving rate limiting steps for AAV vectorsP01HL066973 · NHLBI · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI SAMULSKI, RICHARD J · 2001 to 2005
$9.3M
NHLBI NIH HHS 2P01HL051818NHLBI NIH HHS 5P01HL066973NHLBI NIH HHS P01 HL051818NHLBI NIH HHS P01 HL066973NIDDK NIH HHS P30 DK065988NIGMS NIH HHS 5P01GM05988NIGMS NIH HHS P01 GM059299
6 · The paper itself

Abstract

The limited packaging capacity of adeno-associated virus (AAV) precludes the design of vectors for the treatment of diseases associated with larger genes. Autonomous parvoviruses, such as minute virus of mice and B19, while identical in size (25 nm), are known to package larger genomes of 5.1 and 5.6 kb, respectively, compared to AAV genomes of 4.7 kb. One primary difference is the fact that wild-type (wt) AAV utilizes three capsid subunits instead of two to form the virion shell. In this study, we have characterized the packaging capacity of AAV serotypes 1 through 5 with and without the Vp2 subunit. Using reporter transgene cassettes that range in size from 4.4 to 6.0 kb, we determined that serotypes 1 through 5 with and without Vp2 could successfully package, replicate in, and transduce cells. Dot blot analysis established that packaging efficiency was similar for all vector cassettes and that the integrity of encapsidated genomes was intact regardless of size. Although physical characterization determined that virion structures were indistinguishable from wt, transduction experiments determined that all serotype vectors carrying larger genomes (5.3 kb and higher) transduced cells less efficiently (within a log) than AAV encapsidating wt size genomes. This result was not unique to reporter genes and was observed for CFTR vector cassettes ranging in size from 5.1 to 5.9 kb. No apparent advantage in packaging efficiency was observed when Vp2 was present or absent from the virion. Further analysis determined that a postentry step was responsible for the block in infection and specific treatment of cells upon infection with proteasome inhibitors increased transduction of AAV encapsidating larger DNA templates to wt levels, suggesting a preferential degradation of virions encapsidating larger-than-wt genomes. This study illustrates that AAV is capable of packaging and protecting recombinant genomes as large as 6.0 kb but the larger genome-containing virions are preferentially degraded by the proteasome and that this block can be overcome by the addition of proteasome inhibitors.

Indexed as

Genome, ViralVirus AssemblyAnimalsCapsid ProteinsChlorocebus aethiopsCOS CellsCystic Fibrosis Transmembrane Conductance RegulatorDependovirusGene DeletionGene ExpressionGenetic VectorsHumansCapsid ProteinsCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorVP2 protein, Dependovirus

Identifiers

PMID16014954
PMCPMC1181570
OpenAlexW1995793532

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.